Salix Coronary Plaque vs AI-CVD

Similar category, different focus. These tools serve overlapping but distinct needs. Comparability 70/100 Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.

Salix Coronary Plaque

by Artrya Limited

AI-CVD

by HeartLung Corporation

AI Verdict

Tool A, Salix Coronary Plaque, specializes in detailed coronary artery plaque and stenosis assessment from CCTA scans, providing in-depth analysis of atherosclerosis and high-risk plaque features. In contrast, Tool B, AI-CVD, focuses on opportunistic screening for broader cardiovascular and multisystem diseases by leveraging existing chest and abdominal CT scans to identify hidden health risks. While both offer coronary artery calcium scoring, their distinct input requirements and primary clinical applications make them complementary rather than direct substitutes.

Choose Salix Coronary Plaque if…

Choose Salix Coronary Plaque if your primary need is a rapid, detailed, and point-of-care assessment of coronary artery disease directly from CCTA scans. This tool is ideal for clinicians requiring precise quantification of plaque burden, identification of high-risk plaque features, and accurate stenosis assessment to guide immediate treatment decisions for patients with suspected or known CAD.

View Salix Coronary Plaque →

Choose AI-CVD if…

Choose AI-CVD if you aim to implement opportunistic screening for cardiovascular risks using existing chest and abdominal CT scans, without additional imaging or workflow disruption. This platform is best suited for identifying hidden cardiovascular and multisystem disease indicators, such as coronary artery calcium, valve calcifications, and cardiac chamber abnormalities, in a broad patient population undergoing routine CT imaging for other purposes.

View AI-CVD →

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Quick Comparison

Feature	Salix Coronary Plaque	AI-CVD
Pricing	Contact for pricing	Contact for pricing
Deployment	Cloud	Cloud
FDA Status	Yes AI-estimated	1 AI-estimated

Feature-by-Feature

Detail beyond the Quick Comparison summary. For pricing, deployment, BAA, FDA, and HIPAA see the Overview tab.

Feature	Salix Coronary Plaque	AI-CVD
Name	Salix Coronary Plaque	AI-CVD
Company	Artrya Limited	HeartLung Corporation
Primary Screening Approach	Near real-time, point-of-care assessment of coronary artery plaque and stenosis.	Opportunistic screening for cardiovascular and multisystem diseases using existing CT scans.
Input Scan Type	CCTA scans	Existing chest and abdominal CT scans
Coronary Artery Plaque Analysis	Detection and quantification of coronary plaque (atherosclerosis), identification of high-risk plaque features.	Not specified
Stenosis Assessment	Yes	Not specified
Calcium Scoring	Quantification of calcifications (calcium scoring)	Coronary Artery Calcium (CAC) scoring; Aortic wall, aortic valve, and mitral valve calcium analysis
Cardiac Chamber Volumetry	Not specified	Left Atrium, Left Ventricle, Right Atrium, Right Ventricle

Videos

Demos, reviews, and walkthroughs featuring Salix Coronary Plaque and AI-CVD.

Loading videos…

Videos need JavaScript to load. Search YouTube directly →

View all on YouTube

Frequently Asked Questions

What types of CT scans are analyzed by each tool?

Artrya Salix Coronary Plaque is designed to analyze CCTA scans specifically for coronary artery plaque and stenosis. In contrast, HeartLung AI-CVD performs opportunistic screening using existing chest and abdominal CT scans, without requiring additional imaging, radiation, or contrast.

What are the primary clinical insights each tool provides?

Artrya Salix Coronary Plaque provides a detailed assessment of coronary artery plaque, including high-risk features like low-attenuation plaque and stenosis, along with calcium scoring, to aid in CAD diagnosis. HeartLung AI-CVD offers opportunistic screening for cardiovascular and multisystem diseases, including coronary artery calcium scoring, aortic/mitral valve calcium analysis, cardiac chamber volumetry, epicardial fat volumetry, and aorta/pulmonary artery sizing.

How does each tool integrate into existing clinical workflows?

Artrya Salix Coronary Plaque is designed for near real-time, point-of-care assessment of CCTA scans, featuring integrated workflow management and automated report generation. HeartLung AI-CVD enables opportunistic screening from existing CT scans, aiming for no additional imaging, radiation, contrast, or workflow disruption.

Are there specific reimbursement mechanisms for either tool?

Artrya Salix Coronary Plaque qualifies for a US CPT reimbursement rate of US$950 per assessment for automated plaque analysis of CCTA scans. HeartLung AI-CVD's AutoChamberu2122 module has a new HCPCS code (G0183) for CMS reimbursement for cardiac chamber volume and left ventricular mass, and its AutoBMDu2122 module is reimbursed by Medicare.

What are the key differences in the depth of coronary artery analysis?

Artrya Salix Coronary Plaque focuses on detailed detection and quantification of coronary plaque, including specific high-risk features such as low-attenuation plaque and stenosis assessment. HeartLung AI-CVD provides coronary artery calcium (CAC) scoring but does not detail plaque morphology or stenosis assessment to the same extent.

Does either tool offer insights beyond cardiovascular assessment?

Artrya Salix Coronary Plaque is primarily focused on coronary artery disease diagnosis and assessment from CCTA scans. HeartLung AI-CVD is designed for opportunistic screening of cardiovascular and multisystem diseases, including bone mineral density and liver fat analysis from existing CT scans.

More Comparisons

Assert-IQ vs Rapid Enterprise Platform

AISAP Cardio vs Rapid Enterprise Platform

AngioWaveNet vs Rapid Enterprise Platform

CorVista System with PH Add-On vs Rapid Enterprise Platform